Life Science Investing NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
Life Science Investing NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Life Science Investing NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Life Science Investing NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Life Science Investing NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Life Science Investing I-MAB Transitions to NovaBridge Biosciences with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Life Science Investing I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Life Science Investing I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
Life Science Investing I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
